Lartruvo
Eli Lilly to withdraw Lartruvo from market in soft tissue sarcoma following Phase 3 failure
April 26, 2019Medical Communications, Sales and Marketing Cancer, Eli Lilly, Lartruvo, pharma, soft tissue sarcoma
Eli Lilly has revealed it is to withdraw its platelet-derived growth factor receptor alpha (PDGFR-α) blocking antibody Lartruvo (olaratumab) from …
EMA rejects Lilly’s Lartruvo in soft tissue cancer following trial failure
January 24, 2019Sales and Marketing Cancer, EMA, Eli Lilly, Lartruvo, pharma
Eli Lilly has been dealt a blow as the European Medicines Agency announced its recommendation for soft tissue cancer patients …
MSD and Lilly announce immuno-oncology collaboration
January 11, 2017Medical Communications, Research and Development Eli Lilly, Lartruvo, MSD, keytruda, lilly
MSD, known as Merck in North America, and Eli Lilly have announced the expansion of their existing immuno-oncology collaboration. The …
EU recommendation for Lilly’s soft tissue cancer drug
September 19, 2016Sales and Marketing CHMP, EMA, Eli Lilly, Lartruvo, soft tissue sarcoma
The Committee for Medicinal Products for Human Use (CHMP) has recommended Eli Lilly’s Lartruvo (olaratumab) for treatment of adults with …
Latest content
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
